This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.
It is currently introduced in the United States Senate as S. 741 Cancer Drug Parity Act of 2019 and pending in the United States House of Representatives as H.R. 1730, Cancer Drug Parity Act of 2019. The Association of American Cancer Institutes (AACI) officially has endorsed this bill. AACI is a member of and works with the Coalition to Improve Access to Cancer Care (CIACC) to advocate and remain engaged in this legislation.
See Full Bill